PD-L2 based immune signature confers poor prognosis in HNSCC

PD-L2 expression is an important predictor of anti-PD-1 therapy efficacy in patients with head and neck squamous cell carcinoma (HNSCC). However, whether the PD-L2-based immune signature can serve as a prognostic biomarker for patients with HNSCC remains unclear. Here, we reported that PD-L2 was pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Yu, Liu, Chao, Zhang, Xiaoyue, Zhou, Qianqian, Li, Yatian, Xu, Yini, Gao, Zhenyue, Xu, Yiqi, Kong, Lingping, Yang, Aifeng, Mei, Mei, Ren, Yu, Wang, Xudong, Zhou, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344752/
https://www.ncbi.nlm.nih.gov/pubmed/34377590
http://dx.doi.org/10.1080/2162402X.2021.1947569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344752/
https://www.ncbi.nlm.nih.gov/pubmed/34377590
http://dx.doi.org/10.1080/2162402X.2021.1947569

Ejemplares similares